{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T19:23:57Z","timestamp":1766690637518,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.msard.2018.07.026","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T15:32:30Z","timestamp":1531841550000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?"],"prefix":"10.1016","volume":"25","author":[{"given":"Regina Maria","family":"Papais-Alvarenga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-6349","authenticated-orcid":false,"given":"Vanderson Carvalho","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina Ribeiro","family":"de Ara\u00fajo e Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Batista","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Papais","family":"Alvarenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Beatriz Calmon Nogueira da Gama","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Christiany","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helcio","family":"Alvarenga-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcell Pourbaix Morisson","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-0416","authenticated-orcid":false,"given":"Priscila Oliveira","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleonice Melo","family":"Bento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0833-4024","authenticated-orcid":false,"given":"Claudia Cristina Ferreira","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.07.026_bib0001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2006.06.028","article-title":"Antibodies as biological markers for pathophysiological processes in MS","volume":"180","author":"Khalil","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2018.07.026_bib0002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1756285611433772","article-title":"Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more","volume":"5","author":"Mayer","year":"2012","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2018.07.026_bib0003","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody- associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2018.07.026_bib0005","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2018.07.026_bib0006","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1172\/JCI28334","article-title":"Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice","volume":"116","author":"Bettelli","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.msard.2018.07.026_bib0007","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1172\/JCI28330","article-title":"Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell\/B cell cooperation","volume":"116","author":"Krishnamoorthy","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2018.07.026_bib0008","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitisoptica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.07.026_bib0009","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelinoligodendrocyte glycoprotein antibodies in adults with a neuromyelitisoptica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.026_bib0010","first-page":"866","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitisoptica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"MultScler"},{"key":"10.1016\/j.msard.2018.07.026_bib0011","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitisoptica phenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.07.026_bib0012","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"12","key":"10.1016\/j.msard.2018.07.026_bib0013","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes:a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.07.026_bib0014","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive andAQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.026_bib0015","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG inadults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2018.07.026_bib0016","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458515614093","article-title":"The clinical spectrum associated with myelin oligodendrocyteglycoprotein antibodies (anti-MOG-Ab) in Thaipatients","volume":"22","author":"Siritho","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.07.026_bib0017","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s11427-015-4997-y","article-title":"Autoantibody to MOG suggeststwo distinct clinical subtypes of NMOSD","volume":"59","author":"Yan","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.msard.2018.07.026_bib0018","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","article-title":"Neuromyelitisoptica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients","volume":"381","author":"Bouzar","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2018.07.026_bib0019","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.07.026_bib0020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.07.026_bib0021","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1352458515591071","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in auqporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications","volume":"22","author":"Cobo-Calvo","year":"2016","journal-title":"Multiple Sclerosis J."},{"key":"10.1016\/j.msard.2018.07.026_bib0022","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquqporin-4 antibody -negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.026_bib0023","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.026_bib0024","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.07.026_bib0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2018.07.026_bib0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.026_bib0027","unstructured":"Higgins J.P., Green S. Cochrane handbook for systematic reviews of interventions. Voersion 5.1.0. The Cochrane Collaboration; 2011."},{"key":"10.1016\/j.msard.2018.07.026_bib0028","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A s\u00e9rum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.msard.2018.07.026_bib0029","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicenter comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2018.07.026_bib0030","first-page":"148","article-title":"Acute transverse myelitis after Zika virus infection","volume":"23","author":"Neri","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.msard.2018.07.026_bib0031","doi-asserted-by":"crossref","first-page":"e17063","DOI":"10.1371\/journal.pone.0017063","article-title":"The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected","volume":"6","author":"Pena","year":"2011","journal-title":"PLoSOne"},{"issue":"3","key":"10.1016\/j.msard.2018.07.026_bib0032","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/1352458513495580","article-title":"The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project","volume":"20","author":"Papais Alvarenga","year":"2014","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2018.07.026_bib0033","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Pr\u00f6bstel","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.026_bib0034","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2018.07.026_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.msard.2016.03.011","article-title":"Prognostic factors associated with long-term disability and secondary progression in patients with Multiple Sclerosis","volume":"8","author":"Vasconcelos","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2018.07.026_bib0036","doi-asserted-by":"crossref","first-page":"8207","DOI":"10.1073\/pnas.122092499","article-title":"Molecular characterization of antibody specificities against myelin\/oligodendrocyte glycoprotein in autoimmune demyelination","volume":"99","author":"von Budingen","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.msard.2018.07.026_bib0037","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00401-016-1559-8","article-title":"Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen","volume":"132","author":"Kinzel","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.msard.2018.07.026_bib0038","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","article-title":"Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination","volume":"14","author":"Peschl","year":"2017","journal-title":"J. Neuroinflammation"},{"issue":"50","key":"10.1016\/j.msard.2018.07.026_bib0039","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1073\/pnas.0607242103","article-title":"Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis","volume":"103","author":"Zhou","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2018.07.026_bib0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2051-5960-2-35","article-title":"Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain","volume":"2","author":"Saadoun","year":"2014","journal-title":"Acta Neuropathol. Commun."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818302372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818302372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:42:40Z","timestamp":1761900160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818302372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":39,"alternative-id":["S2211034818302372"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.07.026","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}